Australian biotech, Novartis in pact to block transplant rejection

06/5/2006 | Age (Melbourne, Australia), The

Possibly Australia's largest joint drug development deal -- worth up to $287 million -- has been signed between the biotech Cytopia and Novartis to produce products to prevent rejection of transplanted organs. Under the deal, Cytopia will develop drugs that inhibit the JAK3 enzyme from hyperactivating the immune system and causing rejection.

View Full Article in:

Age (Melbourne, Australia), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT